A novel imidazopyridine derivative, X22, attenuates sepsis-induced lung and liver injury by inhibiting the inflammatory response in vitro and in vivo

doi:10.2147/DDDT.S101449

科研成果详情

题名	A novel imidazopyridine derivative, X22, attenuates sepsis-induced lung and liver injury by inhibiting the inflammatory response in vitro and in vivo
作者	Ge, Xiangting 1,2; Feng, Zhiguo 1; Xu, Tingting 2; Wu, Beibei 3; Chen, Hongjin 1; Xu, Fengli3; Fu, Lili 1; Shan, Xiaoou3; Dai, Yuanrong2,4; Zhang, Yali 1; Liang, Guang 1
发表日期	2016-12-31
发表期刊	DRUG DESIGN DEVELOPMENT AND THERAPY 影响因子和分区
语种	英语
原始文献类型	Article
关键词	LPS imidazopyridine derivative sepsis acute lung injury inflammation
其他关键词	ACETYL SALICYLIC-ACID ; ACETYLSALICYLIC-ACID ; DISCOVERY ; ANTAGONIST ; MORTALITY ; SURVIVAL ; ERITORAN ; ANALOGS ; TISSUE ; DRUGS
摘要	Sepsis remains a leading cause of death worldwide. Despite years of extensive research, effective drugs to treat sepsis in the clinic are lacking. In this study, we found a novel imidazopyridine derivative, X22, which has powerful anti-inflammatory activity. X22 dose-dependently inhibited lipopolysaccharide (LPS)-induced proinflammatory cytokine production in mouse primary peritoneal macrophages and RAW 264.7 macrophages. X22 also downregulated the LPS-induced proinflammatory gene expression in vitro. In vivo, X22 exhibited a significant protection against LPS-induced death. Pretreatment or treatment with X22 attenuated the sepsis-induced lung and liver injury by inhibiting the inflammatory response. In addition, X22 showed protection against LPS-induced acute lung injury. We additionally found that pretreatment with X22 reduced the inflammatory pain in the acetic acid and formalin models and reduced the dimethylbenzene-induced ear swelling and acetic acid-increased vascular permeability. Together, these data confirmed that X22 has multiple anti-inflammatory effects and may be a potential therapeutic option in the treatment of inflammatory diseases.
资助项目	National Natural Science Funding of ChinaNational Natural Science Foundation of China (NSFC) [81503123, 81570027, 21272179]; Zhejiang Provincial Natural Science Funding [LQ14H310003]; Funding for Scientific Research of Wenzhou Medical University [QTJ15010]
出版者	DOVE MEDICAL PRESS LTD
出版地	ALBANY
ISSN	1177-8881
卷号	10 页码:1947-1959
DOI	10.2147/DDDT.S101449
页数	13
WOS类目	Chemistry, Medicinal ; Pharmacology & Pharmacy
WOS研究方向	Pharmacology & Pharmacy
WOS记录号	WOS:000390321100001
收录类别	SCIE ; PUBMED ; SCOPUS
URL	查看原文
PubMed ID	27390516
PMC记录号	PMC4930233
SCOPUSEID	2-s2.0-85006833488
通讯作者地址	[Zhang, Yali]Chemical Biology Research Center,School of Pharmaceutical Sciences,Wenzhou Medical University,University Town,Wenzhou,325035,China
Scopus学科分类	Pharmacology;Pharmaceutical Science;Drug Discovery
引用统计	被引频次：12[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/4011
专题	药学院（分析测试中心）附属第二医院第二临床医学院、附属第二医院、育英儿童医院第二临床医学院、附属第二医院、育英儿童医院_儿科学
通讯作者	Zhang, Yali
作者单位	1.Chemical Biology Research Center,School of Pharmaceutical Sciences,Wenzhou,China; 2.Department of Pulmonary Medicine,The 2nd Affiliated Hospital,Wenzhou,China; 3.Department of Pediatrics,The 2nd Affiliated Hospital,Wenzhou Medical University,Wenzhou,China; 4.Department of Pulmonary Medicine,The 2nd Affiliated Hospital,Wenzhou Medical University,Wenzhou,325035,China
通讯作者单位	药学院（分析测试中心）; 生物有机与药物化学研究中心
推荐引用方式 GB/T 7714	Ge, Xiangting,Feng, Zhiguo,Xu, Tingting,et al. A novel imidazopyridine derivative, X22, attenuates sepsis-induced lung and liver injury by inhibiting the inflammatory response in vitro and in vivo[J]. DRUG DESIGN DEVELOPMENT AND THERAPY,2016,10:1947-1959.
APA	Ge, Xiangting., Feng, Zhiguo., Xu, Tingting., Wu, Beibei., Chen, Hongjin., ... & Liang, Guang. (2016). A novel imidazopyridine derivative, X22, attenuates sepsis-induced lung and liver injury by inhibiting the inflammatory response in vitro and in vivo. DRUG DESIGN DEVELOPMENT AND THERAPY, 10, 1947-1959.
MLA	Ge, Xiangting,et al."A novel imidazopyridine derivative, X22, attenuates sepsis-induced lung and liver injury by inhibiting the inflammatory response in vitro and in vivo".DRUG DESIGN DEVELOPMENT AND THERAPY 10(2016):1947-1959.